|
End-of-day quote
Wiener Boerse
2026-08-28
|
5-day change | 1st Jan Change | ||
| 5.490 EUR | -0.72% |
|
-3.00% | +13.66% |
| 08-26 | Lundbeck expands AI partnership with Eversana in the US | FW |
| 08-24 | Lundbeck's Obtains Orphan Designation in EU for Investigational Treatment for Cushing's Syndrome | MT |
Company Valuation: Lundbeck
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 25,433 | 31,719 | 39,416 | 41,398 | 42,670 | - | - |
| Change | - | 24.72% | 24.27% | 5.03% | 3.07% | - | - |
| Enterprise Value (EV) 1 | 27,464 | 31,008 | 51,598 | 49,619 | 46,673 | 42,492 | 38,733 |
| Change | - | 12.91% | 66.4% | -3.84% | -5.94% | -8.96% | -8.85% |
| P/E | 13.5x | 14.2x | 13x | 13.4x | 9.5x | 9.33x | 9.92x |
| PBR | 1.24x | 1.47x | 1.64x | 1.72x | 1.5x | 1.35x | 1.24x |
| PEG | - | 0.7x | 0.3x | 8.5x | 0.2x | 5.1x | -1.65x |
| Capitalization / Revenue | 1.39x | 1.59x | 1.79x | 1.68x | 1.65x | 1.64x | 1.68x |
| EV / Revenue | 1.51x | 1.56x | 2.34x | 2.01x | 1.8x | 1.63x | 1.53x |
| EV / EBITDA | 5.89x | 5.49x | 8.13x | 6.3x | 5.77x | 5.24x | 5.06x |
| EV / EBIT | 9.63x | 9.71x | 15.8x | 9.41x | 7.88x | 6.87x | 6.69x |
| EV / FCF | 10.2x | 8.66x | 18.7x | 10.2x | 7.77x | 7x | 6.93x |
| FCF Yield | 9.83% | 11.5% | 5.35% | 9.8% | 12.9% | 14.3% | 14.4% |
| Dividend per Share 2 | 0.58 | 0.7 | 0.95 | 1.15 | 1.552 | 1.397 | 1.497 |
| Rate of return | 2.23% | 2.14% | 2.3% | 2.66% | 3.6% | 3.24% | 3.47% |
| EPS 2 | 1.93 | 2.31 | 3.17 | 3.22 | 4.545 | 4.628 | 4.35 |
| Distribution rate | 30.1% | 30.3% | 30% | 35.7% | 34.1% | 30.2% | 34.4% |
| Net sales 1 | 18,246 | 19,912 | 22,004 | 24,630 | 25,918 | 26,054 | 25,353 |
| EBITDA 1 | 4,663 | 5,652 | 6,347 | 7,881 | 8,095 | 8,109 | 7,661 |
| EBIT 1 | 2,852 | 3,195 | 3,270 | 5,275 | 5,927 | 6,183 | 5,791 |
| Net income 1 | 1,916 | 2,290 | 3,143 | 3,192 | 4,586 | 4,649 | 4,359 |
| Net Debt 1 | 2,031 | -711 | 12,182 | 8,221 | 4,003 | -177.7 | -3,937 |
| Reference price 2 | 26.05 | 32.76 | 41.32 | 43.16 | 43.16 | 43.16 | 43.16 |
| Nbr of stocks (in thousands) | 992,840 | 992,840 | 992,011 | 991,227 | 991,227 | - | - |
| Announcement Date | 2/7/23 | 2/7/24 | 2/5/25 | 2/4/26 | - | - | - |
1DKK in Million2DKK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 22.67x | 0.25x | 14.23x | 0.41% | 103B | ||
| 22.93x | 0.21x | 12.89x | 0.89% | 54.57B | ||
| 35.55x | 2.68x | 24.11x | 1.69% | 22.16B | ||
| 10.54x | 0.2x | 4.71x | 2.81% | 8.07B | ||
| 13.24x | 0.95x | 7.82x | 3% | 7.11B | ||
| 9.29x | 1.77x | 5.65x | 3.68% | 6.49B | ||
| 5.53x | 0.08x | 2.43x | 5.36% | 6.17B | ||
| 25.03x | 1.14x | 14.35x | 3.06% | 5.12B | ||
| 44.47x | 0.78x | 15.54x | 0.13% | 4.29B | ||
| Average | 21.03x | 0.90x | 11.30x | 2.34% | 24.13B | |
| Weighted average by Cap. | 22.89x | 0.58x | 13.77x | 1.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- HLUN B Stock
- LUNA Stock
- Valuation Lundbeck
Select your edition
All financial news and data tailored to specific country editions
















